| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2012PLoSO...748370B |
| P356 | DOI | 10.1371/JOURNAL.PONE.0048370 |
| P932 | PMC publication ID | 3511462 |
| P698 | PubMed publication ID | 23226202 |
| P5875 | ResearchGate publication ID | 233888807 |
| P2093 | author name string | Tianxia Wu | |
| Daniel S Reich | |||
| Mika Komori | |||
| Bibiana Bielekova | |||
| Quangang Xu | |||
| P2860 | cites work | Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis | Q22252943 |
| Monocyte-like and mature macrophages produce CXCL13 (B cell-attracting chemokine 1) in inflammatory lesions with lymphoid neogenesis | Q24300326 | ||
| Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity | Q24306484 | ||
| The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis | Q24308609 | ||
| IL-12: the role of p40 versus p75 | Q28213086 | ||
| Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study | Q28290823 | ||
| Overlapping roles of CXCL13, interleukin 7 receptor alpha, and CCR7 ligands in lymph node development | Q28585776 | ||
| Chemokine CXCL13 is essential for lymph node initiation and is induced by retinoic acid and neuronal stimulation | Q28585797 | ||
| The chemokine CXCL13 is a key regulator of B cell recruitment to the cerebrospinal fluid in acute Lyme neuroborreliosis. | Q33611768 | ||
| The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS). | Q33654152 | ||
| Analysis of biomarker data: logs, odds ratios, and receiver operating characteristic curves | Q33729360 | ||
| CXCL13 as a cerebrospinal fluid marker for neurosyphilis in HIV-infected patients with syphilis | Q33907970 | ||
| Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. | Q34363246 | ||
| Francisella tularensis LVS-induced Interleukin-12 p40 cytokine production mediates dendritic cell migration through IL-12 Receptor β1. | Q35141375 | ||
| The power of combinatorial immunology: IL-12 and IL-12-related dimeric cytokines in infectious diseases | Q35166988 | ||
| Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients | Q35585366 | ||
| Intrathecal effects of daclizumab treatment of multiple sclerosis | Q35635127 | ||
| Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions | Q36365596 | ||
| IL-12p40: an inherently agonistic cytokine | Q36663486 | ||
| The relation between inflammation and neurodegeneration in multiple sclerosis brains. | Q37181308 | ||
| IL-12 p40 homodimer, the so-called biologically inactive molecule, induces nitric oxide synthase in microglia via IL-12R beta 1. | Q37348848 | ||
| Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis | Q37354974 | ||
| Diagnostic accuracy and receiver-operating characteristics curve analysis in surgical research and decision making | Q37835793 | ||
| Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. | Q39808939 | ||
| IL-8 in cerebrospinal fluid from children with acute encephalopathy is higher than in that from children with febrile seizure | Q40357894 | ||
| Discriminating Lyme neuroborreliosis from other neuroinflammatory diseases by levels of CXCL13 in cerebrospinal fluid. | Q42772808 | ||
| IL-12 p40 homodimer-dependent macrophage chemotaxis and respiratory viral inflammation are mediated through IL-12 receptor beta 1. | Q42833249 | ||
| Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. | Q43227358 | ||
| The ratio of P40 monomer to dimer is an important determinant of IL-12 bioactivity | Q44916973 | ||
| Herpes simplex virus type 1-mediated up-regulation of IL-12 (p40) mRNA expression. Implications in immunopathogenesis and protection. | Q45772138 | ||
| Reduced T helper 1 responses in IL-12 p40 transgenic mice. | Q47829367 | ||
| Meningeal T cells associate with diffuse axonal loss in multiple sclerosis spinal cords | Q48099284 | ||
| Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group | Q48180007 | ||
| Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. | Q48200750 | ||
| Approach to discriminate subgroups in multiple sclerosis with cerebrospinal fluid (CSF) basic inflammation indices and TNF-alpha, IL-1beta, IL-6, IL-8. | Q48230312 | ||
| Production of hemolymphopoietic cytokines (IL-6, IL-8, colony-stimulating factors) by normal human astrocytes in response to IL-1 beta and tumor necrosis factor-alpha | Q48427106 | ||
| Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma | Q48462130 | ||
| Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment | Q48701331 | ||
| Key role of CXCL13/CXCR5 axis for cerebrospinal fluid B cell recruitment in pediatric OMS. | Q50971930 | ||
| Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. | Q51027456 | ||
| Detection of MCP-1 and IL-8 in the serum and cerebrospinal fluid of a child with Miller Fisher syndrome. | Q51608143 | ||
| Differences in the inducible gene expression and protein production of IL-12p40, IL-12p70 and IL-23: involvement of p38 and JNK kinase pathways. | Q54422001 | ||
| BLC (CXCL13) is expressed by different dendritic cell subsets in vitro and in vivo. | Q55034944 | ||
| Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid | Q59543689 | ||
| Expression of the B cell-attracting chemokine CXCL13 in the target organ and autoantibody production in ectopic lymphoid tissue in the chronic inflammatory disease Sjögren's syndrome | Q60548220 | ||
| Systematic microanatomical analysis of CXCL13 and CCL21in situ production and progressive lymphoid organization in rheumatoid synovitis | Q60810884 | ||
| IL-12 p40 messenger RNA expression in target organs during acute graft-versus-host disease. Possible involvement of IFN-gamma | Q71555542 | ||
| The IL-12 p40 homodimer as a specific antagonist of the IL-12 heterodimer | Q71782113 | ||
| Differential effects of IL-12 receptor blockade with IL-12 p40 homodimer on the induction of CD4+ and CD8+ IFN-gamma-producing cells | Q71968307 | ||
| Lymphoid chemokine B cell-attracting chemokine-1 (CXCL13) is expressed in germinal center of ectopic lymphoid follicles within the synovium of chronic arthritis patients | Q73311968 | ||
| IL-8 is a key mediator of neuroinflammation in severe traumatic brain injuries | Q75372669 | ||
| Ectopic expression of the B cell-attracting chemokine BCA-1 (CXCL13) on endothelial cells and within lymphoid follicles contributes to the establishment of germinal center-like structures in Sjögren's syndrome | Q77179303 | ||
| CXCL13 and CCL21 are expressed in ectopic lymphoid follicles in cutaneous lymphoproliferative disorders | Q80316283 | ||
| Characterization of CXCL13+ neoplastic t cells in cutaneous lesions of angioimmunoblastic T-cell lymphoma (AITL) | Q80528624 | ||
| B-Cells in ocular adnexal lymphoproliferative lesions express B-cell attracting chemokine 1 (CXCL13) | Q81021721 | ||
| Diagnostic reliability of cerebral spinal fluid tests for acute confusional state (delirium) in patients with systemic lupus erythematosus: interleukin 6 (IL-6), IL-8, interferon-alpha, IgG index, and Q-albumin | Q81355283 | ||
| Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis | Q81470272 | ||
| Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid | Q82230939 | ||
| Cerebrospinal fluid levels of CXCL13 are elevated in neuromyelitis optica | Q82254306 | ||
| The secreted form of the p40 subunit of interleukin (IL)-12 inhibits IL-23 functions and abrogates IL-23-mediated antitumour effects | Q82305649 | ||
| Induction of lymphotoxin-alpha by interleukin-12 p40 homodimer, the so-called biologically inactive molecule, but not IL-12 p70 | Q82661826 | ||
| IL-6 and IL-8 in cerebrospinal fluid from patients with aseptic meningitis and bacterial meningitis: their potential role as a marker for differential diagnosis | Q83900243 | ||
| P275 | copyright license | Creative Commons CC0 License | Q6938433 |
| P6216 | copyright status | copyrighted, dedicated to the public domain by copyright holder | Q88088423 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cerebrospinal fluid | Q54196 |
| biomarker | Q864574 | ||
| P304 | page(s) | e48370 | |
| P577 | publication date | 2012-11-30 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Cerebrospinal fluid IL-12p40, CXCL13 and IL-8 as a combinatorial biomarker of active intrathecal inflammation | |
| P478 | volume | 7 |
| Q36894072 | Administration of Myelin Basic Protein Peptides Encapsulated in Mannosylated Liposomes Normalizes Level of Serum TNF-α and IL-2 and Chemoattractants CCL2 and CCL4 in Multiple Sclerosis Patients |
| Q55052878 | Advances in Biomarker-Guided Therapy for Pediatric- and Adult-Onset Neuroinflammatory Disorders: Targeting Chemokines/Cytokines. |
| Q47117780 | Amyloid-β Homeostasis Bridges Inflammation, Synaptic Plasticity Deficits and Cognitive Dysfunction in Multiple Sclerosis. |
| Q47094091 | Anti-LINGO-1 has no detectable immunomodulatory effects in preclinical and phase 1 studies |
| Q93209819 | Autism spectrum disorder and severe social impairment associated with elevated plasma interleukin-8 |
| Q41236543 | Autologous Bone Marrow Transplantation in Multiple Sclerosis: Biomarker Relevance for Patient Recruitment and Follow up. |
| Q35364112 | Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel |
| Q35078327 | Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future |
| Q37271834 | CXCL13, CXCL10 and CXCL8 as Potential Biomarkers for the Diagnosis of Neurosyphilis Patients |
| Q47356888 | Cerebrospinal Fluid Cytokine Expression Profile in Multiple Sclerosis and Chronic Inflammatory Demyelinating Polyneuropathy. |
| Q34422726 | Cerebrospinal fluid ceramides from patients with multiple sclerosis impair neuronal bioenergetics |
| Q48737760 | Cerebrospinal fluid inflammatory markers in patients with multiple sclerosis: a pilot study. |
| Q49900631 | Cerebrospinal fluid level of Nogo receptor 1 antagonist lateral olfactory tract usher substance (LOTUS) correlates inversely with the extent of neuroinflammation |
| Q64957483 | Clinical utility of a molecular signature in inflammatory demyelinating disease. |
| Q24273331 | Comprehensive immunophenotyping of cerebrospinal fluid cells in patients with neuroimmunological diseases |
| Q57167230 | Delayed treatment of MS is associated with high CSF levels of IL-6 and IL-8 and worse future disease course |
| Q35848490 | Immune and Epstein-Barr virus gene expression in cerebrospinal fluid and peripheral blood mononuclear cells from patients with relapsing-remitting multiple sclerosis |
| Q34718044 | Intense inflammation and nerve damage in early multiple sclerosis subsides at older age: a reflection by cerebrospinal fluid biomarkers. |
| Q38774697 | Modulation of Neuroinflammation in the Central Nervous System: Role of Chemokines and Sphingolipids |
| Q47615874 | Molecular-based diagnosis of multiple sclerosis and its progressive stage |
| Q26753174 | Parallel Aspects of the Microenvironment in Cancer and Autoimmune Disease |
| Q61449501 | Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis |
| Q40962441 | Pharmacodynamic effects of daclizumab in the intrathecal compartment |
| Q38258595 | Point-of-care diagnostics, a major opportunity for change in traditional diagnostic approaches: potential and limitations |
| Q36188305 | Radiologically isolated syndrome: watchful waiting vs. active treatment |
| Q26852859 | Stage-specific immune dysregulation in multiple sclerosis |
| Q28255460 | Subclinical central inflammation is risk for RIS and CIS conversion to MS |
| Q38819421 | The cerebrospinal fluid in multiple sclerosis: far beyond the bands |
| Q92251928 | Utility of chemokines CCL2, CXCL8, 10 and 13 and interleukin 6 in the pediatric cohort for the recognition of neuroinflammation and in the context of traditional cerebrospinal fluid neuroinflammatory biomarkers |
Search more.